Servier shared a post on LinkedIn:
“We are thrilled to announce that we have acquired a precision therapy with the potential to be ‘best-in-class’ for acute leukemias from BioNova Pharmaceuticals. This acquisition strengthens our leadership in blood cancer and commitment to developing precision medicine in line with our 2030 strategy. At Servier, we have made oncology one of our priority innovation areas. We invest close to 70% of our R&D budget in oncology, with a view to becoming a focused and innovative player in rare cancer treatments.”
More posts featuring Servier.